AAD: Subcutaneous amlitelimab aids atopic dermatitis outcomes through week 24
Amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), is safe and effective, with potentially progressive efficacy over time, for patients with moderate-to-severe ...
4 hours ago
0
1









